|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rahib L, Smith BD, Aizenberg R, Rosenzweig
AB, Fleshman JM and Matrisian LM: Projecting cancer incidence and
deaths to 2030: The unexpected burden of thyroid, liver, and
pancreas cancers in the United States. Cancer Res. 74:2913–2921.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sarantis P, Koustas E, Papadimitropoulou
A, Papavassiliou AG and Karamouzis MV: Pancreatic ductal
adenocarcinoma: Treatment hurdles, tumor microenvironment and
immunotherapy. World J Gastrointest Oncol. 12:173–181. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu JX, Zhao CF, Chen WB, Liu QC, Li QW,
Lin YY and Gao F: Pancreatic cancer: A review of epidemiology,
trend, and risk factors. World J Gastroenterol. 27:4298–4321. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuigan A, Kelly P, Turkington RC, Jones
C, Coleman HG and McCain RS: Pancreatic cancer: A review of
clinical diagnosis, epidemiology, treatment and outcomes. World J
Gastroenterol. 24:4846–4861. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Picozzi VJ, Oh SY, Edwards A, Mandelson
MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS
and Kozarek RA: Five-year actual overall survival in resected
pancreatic cancer: A contemporary single-institution experience
from a multidisciplinary perspective. Ann Surg Oncol. 24:1722–1730.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Von Hoff DD, Ervin T, Arena FP, Chiorean
EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et
al: Increased survival in pancreatic cancer with nab-paclitaxel
plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Conroy T, Hammel P, Hebbar M, Ben
Abdelghani M, Wei AC, Raoul JL, Choné L, Francois E, Artru P, Biagi
JJ, et al: FOLFIRINOX or gemcitabine as adjuvant therapy for
pancreatic cancer. N Engl J Med. 379:2395–2406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Upadhrasta S and Zheng L: Strategies in
developing immunotherapy for pancreatic cancer: Recognizing and
correcting multiple immune 'defects' in the tumor microenvironment.
J Clin Med. 8:14722019. View Article : Google Scholar
|
|
12
|
Beatty GL, O'Hara MH, Lacey SF, Torigian
DA, Nazimuddin F, Chen F, Kulikovskaya IM, Soulen MC, McGarvey M,
Nelson AM, et al: Activity of mesothelin-specific chimeric antigen
receptor T cells against pancreatic carcinoma metastases in a phase
1 trial. Gastroenterology. 155:29–32. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
O'Hara M, O'Reilly E, Rosemarie M,
Varadhachary G, Wainberg ZA, Ko A, Fisher GA, Rahma O, Lyman JP,
Cabanski CR, et al: Abstract CT004: A phase Ib study of CD40
agonistic monoclonal antibody APX005M together with gemcitabine
(Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in
untreated metastatic ductal pancreatic adenocarcinoma (PDAC)
patients. Cancer Res. 79(Suppl 13): CT0042019. View Article : Google Scholar
|
|
14
|
Bahary N, Garrido-Laguna I, Cinar P,
O'Rourke MA, Somer BG, Nyak-Kapoor A, Lee JS, Munn D, Paul Kennedy
E, Vahanian NN, et al: Phase 2 trial of the indoleamine
2,3-dioxygenase pathway (IDO) inhibitor indoximod plus
gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas
cancer: Interim analysis. J Clin Oncol. 34(Suppl 15): S30202016.
View Article : Google Scholar
|
|
15
|
Di Federico A, Tateo V, Parisi C, Formica
F, Carloni R, Frega G, Rizzo A, Ricci D, Di Marco M, Palloni A and
Brandi G: Hacking pancreatic cancer: Present and future of
personalized medicine. Pharmaceuticals (Basel). 14:6772021.
View Article : Google Scholar
|
|
16
|
Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider
M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, et al: Role of
fatty acid synthase in gemcitabine and radiation resistance of
pancreatic cancers. Int J Biochem Mol Biol. 2:89–98.
2011.PubMed/NCBI
|
|
17
|
Viale A, Pettazzoni P, Lyssiotis CA, Ying
H, Sánchez N, Marchesini M, Carugo A, Green T, Seth S, Giuliani V,
et al: Oncogene ablation-resistant pancreatic cancer cells depend
on mitochondrial function. Nature. 514:628–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu M, Liu W, Qin Y, Xu X, Yu X, Zhuo Q
and Ji S: Regulation of metabolic reprogramming by tumor suppressor
genes in pancreatic cancer. Exp Hematol Oncol. 9:232020. View Article : Google Scholar
|
|
19
|
Daemen A, Peterson D, Sahu N, McCord R, Du
X, Liu B, Kowanetz K, Hong R, Moffat J, Gao M, et al: Metabolite
profiling stratifies pancreatic ductal adenocarcinomas into
subtypes with distinct sensitivities to metabolic inhibitors. Proc
Natl Acad Sci USA. 112:E4410–E4417. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karasinska JM, Topham JT, Kalloger SE,
Jang GH, Denroche RE, Culibrk L, Williamson LM, Wong HL, Lee MK,
O'Kane GM, et al: Altered gene expression along the
glycolysis-cholesterol synthesis axis is associated with outcome in
pancreatic cancer. Clin Cancer Res. 26:135–146. 2020. View Article : Google Scholar
|
|
21
|
Halbrook CJ and Lyssiotis CA: Employing
metabolism to improve the diagnosis and treatment of pancreatic
cancer. Cancer Cell. 31:5–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Perusina Lanfranca M, Thompson JK, Bednar
F, Halbrook C, Lyssiotis C, Levi B and Frankel TL: Metabolism and
epigenetics of pancreatic cancer stem cells. Semin Cancer Biol.
57:19–26. 2019. View Article : Google Scholar :
|
|
23
|
Perera RM and Bardeesy N: Pancreatic
cancer metabolism: Breaking it down to build it back up. Cancer
Discov. 5:1247–1261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dal Molin M, Zhang M, De Wilde RF,
Ottenhof NA, Rezaee N, Wolfgang CL, Blackford A, Vogelstein B,
Kinzler KW, Papadopoulos N, et al: Very long-term survival
following resection for pancreatic cancer is not explained by
commonly mutated genes: Results of whole-exome sequencing analysis.
Clin Cancer Res. 21:1944–1950. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Collisson EA, Sadanandam A, Olson P, Gibb
WJ, Truitt M, Gu S, Cooc J, Weinkle J, Kim GE, Jakkula L, et al:
Subtypes of pancreatic ductal adenocarcinoma and their differing
responses to therapy. Nat Med. 17:500–503. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Moffitt RA, Marayati R, Flate EL, Volmar
KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung
AH, et al: Virtual microdissection identifies distinct tumor- and
stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat
Genet. 47:1168–1178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao L, Zhao H and Yan H: Gene expression
profiling of 1200 pancreatic ductal adenocarcinoma reveals novel
subtypes. BMC Cancer. 18:6032018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Maurer C, Holmstrom SR, He J, Laise P, Su
T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, et
al: Experimental microdissection enables functional harmonisation
of pancreatic cancer subtypes. Gut. 68:1034–1043. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chan-Seng-Yue M, Kim JC, Wilson GW, Ng K,
Figueroa EF, O'Kane GM, Connor AA, Denroche RE, Grant RC, McLeod J,
et al: Transcription phenotypes of pancreatic cancer are driven by
genomic events during tumor evolution. Nat Genet. 52:231–240. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lonardo E, Frias-Aldeguer J, Hermann PC
and Heeschen C: Pancreatic stellate cells form a niche for cancer
stem cells and promote their self-renewal and invasiveness. Cell
Cycle. 11:1282–1290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Richards KE, Zeleniak AE, Fishel ML, Wu J,
Littlepage LE and Hill R: Cancer-associated fibroblast exosomes
regulate survival and proliferation of pancreatic cancer cells.
Oncogene. 36:1770–1778. 2017. View Article : Google Scholar :
|
|
32
|
Mejia I, Bodapati S, Chen KT and Díaz B:
Pancreatic adenocarcinoma invasiveness and the tumor
microenvironment: From biology to clinical trials. Biomedicines.
8:4012020. View Article : Google Scholar :
|
|
33
|
Sherman MH, Yu RT, Tseng TW, Sousa CM, Liu
S, Truitt ML, He N, Ding N, Liddle C, Atkins AR, et al: Stromal
cues regulate the pancreatic cancer epigenome and metabolome. Proc
Natl Acad Sci USA. 114:1129–1134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sousa CM, Biancur DE, Wang X, Halbrook CJ,
Sherman MH, Zhang L, Kremer D, Hwang RF, Witkiewicz AK, Ying H, et
al: Pancreatic stellate cells support tumour metabolism through
autophagic alanine secretion. Nature. 536:479–483. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tape CJ, Ling S, Dimitriadi M, McMahon KM,
Worboys JD, Leong HS, Norrie IC, Miller CJ, Poulogiannis G,
Lauffenburger DA and Jørgensen C: Oncogenic KRAS regulates tumor
cell signaling via stromal reciprocation. Cell. 165:910–920. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Juiz N, Elkaoutari A, Bigonnet M, Gayet O,
Roques J, Nicolle R, Iovanna J and Dusetti N: Basal-like and
classical cells coexistence in pancreatic cancer revealed by single
cell analysis. bioRxiv. 2020.
|
|
37
|
Suzuki T, Otsuka M, Seimiya T, Iwata T,
Kishikawa T and Koike K: The biological role of metabolic
reprogramming in pancreatic cancer. MedComm (2020). 1:302–310.
2020.
|
|
38
|
Zaidi N, Lupien L, Kuemmerle NB, Kinlaw
WB, Swinnen JV and Smans K: Lipogenesis and lipolysis: The pathways
exploited by the cancer cells to acquire fatty acids. Prog Lipid
Res. 52:585–589. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sancho P, Burgos-Ramos E, Tavera A, Bou
Kheir T, Jagust P, Schoenhals M, Barneda D, Sellers K,
Campos-Olivas R, Graña O, et al: MYC/PGC-1α balance determines the
metabolic phenotype and plasticity of pancreatic cancer stem cells.
Cell Metab. 22:590–605. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kamphorst JJ, Nofal M, Commisso C, Hackett
SR, Lu W, Grabocka E, Vander Heiden MG, Miller G, Drebin JA,
Bar-Sagi D, et al: Human pancreatic cancer tumors are nutrient poor
and tumor cells actively scavenge extracellular protein. Cancer
Res. 75:544–553. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yoshida GJ: Metabolic reprogramming: The
emerging concept and associated therapeutic strategies. J Exp Clin
Cancer Res. 34:1112015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu M, Zhou Q, Zhou Y, Fu Z, Tan L, Ye X,
Zeng B, Gao W, Zhou J, Liu Y, et al: Metabolic phenotypes in
pancreatic cancer. PLoS One. 10:e01151532015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lomberk G, Blum Y, Nicolle R, Nair A,
Gaonkar KS, Marisa L, Mathison A, Sun Z, Yan H, Elarouci N, et al:
Distinct epigenetic landscapes underlie the pathobiology of
pancreatic cancer subtypes. Nat Commun. 9:19782018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kaoutari AE, Fraunhoffer NA, Hoare O,
Teyssedou C, Soubeyran P, Gayet O, Roques J, Lomberk G, Urrutia R,
Dusetti N and Iovanna J: Metabolomic profiling of pancreatic
adenocarcinoma reveals key features driving clinical outcome and
drug resistance. EBioMedicine. 66:1033322021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu Q, Ge W, Wang T, Lan J,
Martínez-Jarquín S, Wolfrum C, Stoffel M and Zenobi R:
High-throughput single-cell mass spectrometry reveals abnormal
lipid metabolism in pancreatic ductal adenocarcinoma. Angew Chem
Int Ed Engl. 60:24534–24542. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Argüello RJ, Combes AJ, Char R, Gigan JP,
Baaziz AI, Bousiquot E, Camosseto V, Samad B, Tsui J, Yan P, et al:
SCENITH: A flow cytometry-based method to functionally profile
energy metabolism with single-cell resolution. Cell Metab.
32:1063–1075.e7. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Miller A, Nagy C, Knapp B, Laengle J,
Ponweiser E, Groeger M, Starkl P, Bergmann M, Wagner O and Haschemi
A: Exploring metabolic configurations of single cells within
complex tissue microenvironments. Cell Metab. 26:788–800.e6. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ambrosini G, Dalla Pozza E, Fanelli G, Di
Carlo C, Vettori A, Cannino G, Cavallini C, Carmona-Carmona CA,
Brandi J, Rinalducci S, et al: Progressively de-differentiated
pancreatic cancer cells shift from glycolysis to oxidative
metabolism and gain a quiescent stem state. Cells. 9:15722020.
View Article : Google Scholar :
|
|
49
|
Biancur DE, Paulo JA, Małachowska B,
Quiles Del Rey M, Sousa CM, Wang X, Sohn ASW, Chu GC, Gygi SP,
Harper JW, et al: Compensatory metabolic networks in pancreatic
cancers upon perturbation of glutamine metabolism. Nat Commun.
8:159652017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg's contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Liu XS, Little JB and Yuan ZM: Glycolytic
metabolism influences global chromatin structure. Oncotarget.
6:4214–4225. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Liberti MV and Locasale JW: The Warburg
effect: How does it benefit cancer cells? Trends Biochem Sci.
41:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Husain Z, Huang Y, Seth P and Sukhatme VP:
Tumor-derived lactate modifies antitumor immune response: Effect on
myeloid-derived suppressor cells and NK cells. J Immunol.
191:1486–1495. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Du J, Gu J, Deng J, Kong L, Guo Y, Jin C,
Bao Y, Fu D and Li J: The expression and survival significance of
glucose transporter-1 in pancreatic cancer: Meta-analysis,
bioinformatics analysis and retrospective study. Cancer Invest.
39:741–755. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Lee EE, Ma J, Sacharidou A, Mi W, Salato
VK, Nguyen N, Jiang Y, Pascual JM, North PE, Shaul PW, et al: A
protein kinase C phosphorylation motif in GLUT1 affects glucose
transport and is mutated in GLUT1 deficiency syndrome. Mol Cell.
58:845–853. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Cheng CS, Tan HY, Wang N, Chen L, Meng Z,
Chen Z and Feng Y: Functional inhibition of lactate dehydrogenase
suppresses pancreatic adenocarcinoma progression. Clin Transl Med.
11:e4672021. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Ying H, Kimmelman AC, Lyssiotis CA, Hua S,
Chu GC, Fletcher-Sananikone E, Locasale JW, Son J, Zhang H, Coloff
JL, et al: Oncogenic Kras maintains pancreatic tumors through
regulation of anabolic glucose metabolism. Cell. 149:656–670. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jiang W, Qiao L, Zuo D, Qin D, Xiao J, An
H, Wang Y, Zhang X, Jin Y and Ren L: Aberrant lactate dehydrogenase
A signaling contributes metabolic signatures in pancreatic cancer.
Ann Transl Med. 9:3582021. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Yalcin A, Solakoglu TH, Ozcan SC, Guzel S,
Peker S, Celikler S, Balaban BD, Sevinc E, Gurpinar Y and Chesney
JA: 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase-3 is
required for transforming growth factor β1-enhanced invasion of
Panc1 cells in vitro. Biochem Biophys Res Commun. 484:687–693.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ji S, Zhang B, Liu J, Qin Y, Liang C, Shi
S, Jin K, Liang D, Xu W, Xu H, et al: ALDOA functions as an
oncogene in the highly metastatic pancreatic cancer. Cancer Lett.
374:127–135. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Principe M, Borgoni S, Cascione M,
Chattaragada MS, Ferri-Borgogno S, Capello M, Bulfamante S,
Chapelle J, Di Modugno F, Defilippi P, et al: Alpha-enolase (ENO1)
controls alpha v/beta 3 integrin expression and regulates
pancreatic cancer adhesion, invasion, and metastasis. J Hematol
Oncol. 10:162017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Principe M, Ceruti P, Shih NY,
Chattaragada MS, Rolla S, Conti L, Bestagno M, Zentilin L, Yang SH,
Migliorini P, et al: Targeting of surface alpha-enolase inhibits
the invasiveness of pancreatic cancer cells. Oncotarget.
6:11098–11113. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Azoitei N, Becher A, Steinestel K, Rouhi
A, Diepold K, Genze F, Simmet T and Seufferlein T: PKM2 promotes
tumor angiogenesis by regulating HIF-1α through NF-κB activation.
Mol Cancer. 15:32016. View Article : Google Scholar
|
|
64
|
Thews O and Riemann A: Tumor pH and
metastasis: A malignant process beyond hypoxia. Cancer Metastasis
Rev. 38:113–129. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Guillaumond F, Leca J, Olivares O, Lavaut
MN, Vidal N, Berthezène P, Dusetti NJ, Loncle C, Calvo E, Turrini
O, et al: Strengthened glycolysis under hypoxia supports tumor
symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.
Proc Natl Acad Sci USA. 110:3919–3924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kirk P, Wilson MC, Heddle C, Brown MH,
Barclay AN and Halestrap AP: CD147 is tightly associated with
lactate transporters MCT1 and MCT4 and facilitates their cell
surface expression. EMBO J. 19:3896–3904. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Semenza GL: Tumor metabolism: Cancer cells
give and take lactate. J Clin Invest. 118:3835–3837.
2008.PubMed/NCBI
|
|
68
|
Sun X, Wang M, Wang M, Yao L, Li X, Dong
H, Li M, Sun T, Liu X, Liu Y and Xu Y: Role of proton-coupled
monocarboxylate transporters in cancer: From metabolic crosstalk to
therapeutic potential. Front cell Dev Biol. 8:6512020. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Pavlides S, Whitaker-Menezes D,
Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro
MC, Wang C, Fortina P, Addya S, et al: The reverse Warburg effect:
Aerobic glycolysis in cancer associated fibroblasts and the tumor
stroma. Cell Cycle. 8:3984–4001. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Benny S, Mishra R, Manojkumar MK and
Aneesh TP: From Warburg effect to reverse Warburg effect; the new
horizons of anti-cancer therapy. Med Hypotheses. 144:1102162020.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Roland CL, Arumugam T, Deng D, Liu SH,
Philip B, Gomez S, Burns WR, Ramachandran V, Wang H,
Cruz-Monserrate Z and Logsdon CD: Cell surface lactate receptor
GPR81 is crucial for cancer cell survival. Cancer Res.
74:5301–5310. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Benton CR, Yoshida Y, Lally J, Han X-X,
Hatta H and Bonen A: PGC-1alpha increases skeletal muscle lactate
uptake by increasing the expression of MCT1 but not MCT2 or MCT4.
Physiol Genomics. 35:45–54. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Cheng CF, Ku HC and Lin H: PGC-1α as a
pivotal factor in lipid and metabolic regulation. Int J Mol Sci.
19:34472018. View Article : Google Scholar
|
|
74
|
Schneiderhan W, Scheler M, Holzmann KH,
Marx M, Gschwend JE, Bucholz M, Gress TM, Seufferlein T, Adler G
and Oswald F: CD147 silencing inhibits lactate transport and
reduces malignant potential of pancreatic cancer cells in in vivo
and in vitro models. Gut. 58:1391–1398. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Lee SH, Hwang HK, Lee WJ and Kang CM: MCT4
as a potential therapeutic target to augment gemcitabine
chemosensitivity in resected pancreatic cancer. Cell Oncol (Dordr).
44:1363–1371. 2021. View Article : Google Scholar
|
|
76
|
Benjamin D, Robay D, Hindupur SK, Pohlmann
J, Colombi M, El-Shemerly MY, Maira SM, Moroni C, Lane HA and Hall
MN: Dual inhibition of the lactate transporters MCT1 and MCT4 Is
synthetic lethal with metformin due to NAD+ depletion in
cancer cells. Cell Rep. 25:3047–3058.e4. 2018. View Article : Google Scholar
|
|
77
|
Sonveaux P, Végran F, Schroeder T, Wergin
MC, Verrax J, Rabbani ZN, De Saedeleer CJ, Kennedy KM, Diepart C,
Jordan BF, et al: Targeting lactate-fueled respiration selectively
kills hypoxic tumor cells in mice. J Clin Invest. 118:3930–3942.
2008.PubMed/NCBI
|
|
78
|
Wu DH, Liang H, Lu SN, Wang H, Su ZL,
Zhang L, Ma JQ, Guo M, Tai S and Yu S: miR-124 suppresses
pancreatic ductal adenocarcinoma growth by regulating
monocarboxylate transporter 1-mediated cancer lactate metabolism.
Cell Physiol Biochem. 50:924–935. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lau AN, Li Z, Danai LV, Westermark AM,
Darnell AM, Ferreira R, Gocheva V, Sivanand S, Lien EC, Sapp KM, et
al: Dissecting cell-type-specific metabolism in pancreatic ductal
adenocarcinoma. Elife. 9:e567822020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Koundouros N and Poulogiannis G:
Reprogramming of fatty acid metabolism in cancer. Br J Cancer.
122:4–22. 2020. View Article : Google Scholar :
|
|
81
|
Alo PL, Amini M, Piro F, Pizzuti L,
Sebastiani V, Botti C, Murari R, Zotti G and Di Tondo U:
Immunohistochemical expression and prognostic significance of fatty
acid synthase in pancreatic carcinoma. Anticancer Res.
27:2523–2527. 2007.PubMed/NCBI
|
|
82
|
Li N, Lu H, Chen C, Bu X and Huang P: Loss
of fatty acid synthase inhibits the 'hER2-PI3K/Akt axis' activity
and malignant phenotype of Caco-2 cells. Lipids Health Dis.
12:832013. View Article : Google Scholar
|
|
83
|
Menendez JA, Decker JP and Lupu R: In
support of fatty acid synthase (FAS) as a metabolic oncogene:
Extracellular acidosis acts in an epigenetic fashion activating FAS
gene expression in cancer cells. J Cell Biochem. 94:1–4. 2005.
View Article : Google Scholar
|
|
84
|
Shetty A, Nagesh PKB, Setua S, Hafeez BB,
Jaggi M, Yallapu MM and Chauhan SC: Novel paclitaxel
nanoformulation impairs de novo lipid synthesis in pancreatic
cancer cells and enhances gemcitabine efficacy. ACS Omega.
5:8982–8991. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Tracz-Gaszewska Z and Dobrzyn P:
Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment
of cancer. Cancers (Basel). 11:9482019. View Article : Google Scholar
|
|
86
|
Rysman E, Brusselmans K, Scheys K,
Timmermans L, Derua R, Munck S, Van Veldhoven PP, Waltregny D,
Daniëls VW, Machiels J, et al: De novo lipogenesis protects cancer
cells from free radicals and chemotherapeutics by promoting
membrane lipid saturation. Cancer Res. 70:8117–8126. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Fritz V, Benfodda Z, Rodier G, Henriquet
C, Iborra F, Avancès C, Allory Y, de la Taille A, Culine S, Blancou
H, et al: Abrogation of de novo lipogenesis by stearoyl-CoA
desaturase 1 inhibition interferes with oncogenic signaling and
blocks prostate cancer progression in mice. Mol Cancer Ther.
9:1740–1754. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Eser S, Schnieke A, Schneider G and Saur
D: Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer.
111:817–822. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Menendez JA: Fine-tuning the
lipogenic/lipolytic balance to optimize the metabolic requirements
of cancer cell growth: Molecular mechanisms and therapeutic
perspectives. Biochim Biophys Acta. 1801:381–391. 2010. View Article : Google Scholar
|
|
90
|
Xu M, Jung X, Hines OJ, Eibl G and Chen Y:
Obesity and pancreatic cancer: Overview of epidemiology and
potential prevention by weight loss. Pancreas. 47:158–162. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Li D, Morris JS, Liu J, Hassan MM, Day RS,
Bondy ML and Abbruzzese JL: Body mass index and risk, age of onset,
and survival in patients with pancreatic cancer. JAMA.
301:2553–2562. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Kasenda B, Bass A, Koeberle D, Pestalozzi
B, Borner M, Herrmann R, Jost L, Lohri A and Hess V: Survival in
overweight patients with advanced pancreatic carcinoma: A
multicentre cohort study. BMC Cancer. 14:7282014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Anderson AS, Renehan AG, Saxton JM, Bell
J, Cade J, Cross AJ, King A, Riboli E, Sniehotta F, Treweek S, et
al: Cancer prevention through weight control-where are we in 2020?
Br J Cancer. 124:1049–1056. 2021. View Article : Google Scholar
|
|
94
|
Jacobs EJ, Newton CC, Patel AV, Stevens
VL, Islami F, Flanders WD and Gapstur SM: The association between
body mass index and pancreatic cancer: Variation by age at body
mass index assessment. Am J Epidemiol. 189:108–115. 2020.
View Article : Google Scholar
|
|
95
|
Chimento A, Casaburi I, Avena P, Trotta F,
De Luca A, Rago V, Pezzi V and Sirianni R: Cholesterol and its
metabolites in tumor growth: Therapeutic potential of statins in
cancer treatment. Front Endocrinol (Lausanne). 9:8072019.
View Article : Google Scholar
|
|
96
|
Guillaumond F, Bidaut G, Ouaissi M,
Servais S, Gouirand V, Olivares O, Lac S, Borge L, Roques J, Gayet
O, et al: Cholesterol uptake disruption, in association with
chemotherapy, is a promising combined metabolic therapy for
pancreatic adenocarcinoma. Proc Natl Acad Sci USA. 112:2473–2478.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Nam GH, Kwon M, Jung H, Ko E, Kim SA, Choi
Y, Song SJ, Kim S, Lee Y, Kim GB, et al: Statin-mediated inhibition
of RAS prenylation activates ER stress to enhance the
immunogenicity of KRAS mutant cancer. J Immunother cancer.
9:e0024742021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Jiang W, Hu JW, He XR, Jin WL and He XY:
Statins: A repurposed drug to fight cancer. J Exp Clin Cancer Res.
40:2412021. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Osmak M: Statins and cancer: Current and
future prospects. Cancer Lett. 324:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Kawata S, Yamasaki E, Nagase T, Inui Y,
Ito N, Matsuda Y, Inada M, Tamura S, Noda S, Imai Y and Matsuzawa
Y: Effect of pravastatin on survival in patients with advanced
hepatocellular carcinoma. A randomized controlled trial. Br J
Cancer. 84:886–891. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Lersch C, Schmelz R, Erdmann J, Hollweck
R, Schulte-Frohlinde E, Eckel F, Nader M and Schusdziarra V:
Treatment of HCC with pravastatin, octreotide, or gemcitabine-a
critical evaluation. Hepatogastroenterology. 51:1099–1103.
2004.PubMed/NCBI
|
|
102
|
Butera A, Roy M, Zampieri C, Mammarella E,
Panatta E, Melino G, D'Alessandro A and Amelio I: p53-driven
lipidome influences non-cell-autonomous lysophospholipids in
pancreatic cancer. Biol Direct. 17:62022. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Zhang L, Jin H, Guo X, Yang Z, Zhao L,
Tang S, Mo P, Wu K, Nie Y, Pan Y and Fan D: Distinguishing
pancreatic cancer from chronic pancreatitis and healthy individuals
by (1)H nuclear magnetic resonance-based metabonomic profiles. Clin
Biochem. 45:1064–1069. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Urayama S, Zou W, Brooks K and Tolstikov
V: Comprehensive mass spectrometry based metabolic profiling of
blood plasma reveals potent discriminatory classifiers of
pancreatic cancer. Rapid Commun Mass Spectrom. 24:613–620. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Wang G, Yao H, Gong Y, Lu Z, Pang R, Li Y,
Yung Y, Song H, Liu J, Jin Y, et al: Metabolic detection and
systems analyses of pancreatic ductal adenocarcinoma through
machine learning, lipidomics, and multi-omics. Sci Adv.
7:eabh27242021. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Fang F, He X, Deng H, Chen Q, Lu J, Spraul
M and Yu Y: Discrimination of metabolic profiles of pancreatic
cancer from chronic pancreatitis by high-resolution magic angle
spinning 1H nuclear magnetic resonance and principal components
analysis. Cancer Sci. 98:1678–1682. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Wang Z, Liu F, Fan N, Zhou C, Li D,
Macvicar T, Dong Q, Bruns CJ and Zhao Y: Targeting glutaminolysis:
New perspectives to understand cancer development and novel
strategies for potential target therapies. Front Oncol.
10:5895082020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
DeBerardinis RJ, Mancuso A, Daikhin E,
Nissim I, Yudkoff M, Wehrli S and Thompson CB: Beyond aerobic
glycolysis: Transformed cells can engage in glutamine metabolism
that exceeds the requirement for protein and nucleotide synthesis.
Proc Natl Acad Sci USA. 104:19345–19350. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Ghanem N, El-Baba C, Araji K, El-Khoury R,
Usta J and Darwiche N: The pentose phosphate pathway in cancer:
Regulation and therapeutic opportunities. Chemotherapy. 66:179–191.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Ju HQ, Lin JF, Tian T, Xie D and Xu RH:
NADPH homeostasis in cancer: Functions, mechanisms and therapeutic
implications. Signal Transduct Target Ther. 5:2312020. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Badgley MA, Kremer DM, Maurer HC,
DelGiorno KE, Lee HJ, Purohit V, Sagalovskiy IR, Ma A, Kapilian J,
Firl CEM, et al: Cysteine depletion induces pancreatic tumor
ferroptosis in mice. Science. 368:85–89. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Hatzivassiliou G, Zhao F, Bauer DE,
Andreadis C, Shaw AN, Dhanak D, Hingorani SR, Tuveson DA and
Thompson CB: ATP citrate lyase inhibition can suppress tumor cell
growth. Cancer Cell. 8:311–321. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Akella NM, Ciraku L and Reginato MJ:
Fueling the fire: Emerging role of the hexosamine biosynthetic
pathway in cancer. BMC Biol. 17:522019. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Tong X, Zhao F and Thompson CB: The
molecular determinants of de novo nucleotide biosynthesis in cancer
cells. Curr Opin Genet Dev. 19:32–37. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Wang Y, Bai C, Ruan Y, Liu M, Chu Q, Qiu
L, Yang C and Li B: Coordinative metabolism of glutamine carbon and
nitrogen in proliferating cancer cells under hypoxia. Nat Commun.
10:2012019. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Bott AJ, Shen J, Tonelli C, Zhan L,
Sivaram N, Jiang YP, Yu X, Bhatt V, Chiles E, Zhong H, et al:
Glutamine anabolism plays a critical role in pancreatic cancer by
coupling carbon and nitrogen metabolism. Cell Rep. 29:1287–1298.e6.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Li T and Le A: Glutamine metabolism in
cancer. The Heterogeneity of Cancer Metabolism. Le A: Springer
International Publishing; Cham: pp. 13–32. 2018, View Article : Google Scholar
|
|
118
|
Son J, Lyssiotis CA, Ying H, Wang X, Hua
S, Ligorio M, Perera RM, Ferrone CR, Mullarky E, Shyh-Chang N, et
al: Glutamine supports pancreatic cancer growth through a
KRAS-regulated metabolic pathway. Nature. 496:101–105. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Li W, Chen C, Zhao X, Ye H, Zhao Y, Fu Z,
Pan W, Zheng S, Wei L, Nong T, et al: HIF-2α regulates
non-canonical glutamine metabolism via activation of PI3K/mTORC2
pathway in human pancreatic ductal adenocarcinoma. J Cell Mol Med.
21:2896–2908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Raho S, Capobianco L, Malivindi R, Vozza
A, Piazzolla C, De Leonardis F, Gorgoglione R, Scarcia P, Pezzuto
F, Agrimi G, et al: KRAS-regulated glutamine metabolism requires
UCP2-mediated aspartate transport to support pancreatic cancer
growth. Nat Metab. 2:1373–1381. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Yang S, Hwang S, Kim M, Seo SB, Lee JH and
Jeong SM: Mitochondrial glutamine metabolism via GOT2 supports
pancreatic cancer growth through senescence inhibition. Cell Death
Dis. 9:552018. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Wise DR, Deberardinis RJ, Mancuso A, Sayed
N, Zhang XY, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon
SB and Thompson CB: Myc regulates a transcriptional program that
stimulates mitochondrial glutaminolysis and leads to glutamine
addiction. Proc Natl Acad Sci USA. 105:18782–18787. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Gao P, Tchernyshyov I, Chang TC, Lee YS,
Kita K, Ochi T, Zeller KI, De Marzo AM, Van Eyk JE, Mendell JT and
Dang CV: c-Myc suppression of miR-23a/b enhances mitochondrial
glutaminase expression and glutamine metabolism. Nature.
458:762–765. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Roux C, Riganti C, Borgogno SF, Curto R,
Curcio C, Catanzaro V, Digilio G, Padovan S, Puccinelli MP,
Isabello M, et al: Endogenous glutamine decrease is associated with
pancreatic cancer progression. Oncotarget. 8:95361–95376. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
He J, Li F, Zhou Y, Hou X, Liu S, Li X,
Zhang Y, Jing X and Yang L: LncRNA XLOC_006390 promotes pancreatic
carcinogenesis and glutamate metabolism by stabilizing c-Myc.
Cancer Lett. 469:419–428. 2020. View Article : Google Scholar
|
|
126
|
Lowman XH, Hanse EA, Yang Y, Ishak Gabra
MB, Tran TQ, Li H and Kong M: p53 Promotes cancer cell adaptation
to glutamine deprivation by upregulating Slc7a3 to increase
arginine uptake. Cell Rep. 26:3051–3060.e4. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Tajan M, Hock AK, Blagih J, Robertson NA,
Labuschagne CF, Kruiswijk F, Humpton TJ, Adams PD and Vousden KH: A
role for p53 in the adaptation to glutamine starvation through the
expression of SLC1A3. Cell Metab. 28:721–736.e6. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Tran TQ, Lowman XH, Reid MA,
Mendez-Dorantes C, Pan M, Yang Y and Kong M: Tumor-associated
mutant p53 promotes cancer cell survival upon glutamine deprivation
through p21 induction. Oncogene. 36:1991–2001. 2017. View Article : Google Scholar :
|
|
129
|
Dey P, Baddour J, Muller F, Wu CC, Wang H,
Liao WT, Lan Z, Chen A, Gutschner T, Kang Y, et al: Genomic
deletion of malic enzyme 2 confers collateral lethality in
pancreatic cancer. Nature. 542:119–123. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Dai Z, Ramesh V and Locasale JW: The
evolving metabolic landscape of chromatin biology and epigenetics.
Nat Rev Genet. 21:737–753. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Wang G and Han JJ: Connections between
metabolism and epigenetic modifications in cancer. Med Rev.
1:199–221. 2021. View Article : Google Scholar
|
|
132
|
Etchegaray JP and Mostoslavsky R:
Interplay between metabolism and epigenetics: A nuclear adaptation
to environmental changes. Mol Cell. 62:695–711. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Kottakis F, Nicolay BN, Roumane A, Karnik
R, Gu H, Nagle JM, Boukhali M, Hayward MC, Li YY, Chen T, et al:
LKB1 loss links serine metabolism to DNA methylation and
tumorigenesis. Nature. 539:390–395. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wang H, Li QF, Chow H, Choi S and Leung
YC: Arginine deprivation inhibits pancreatic cancer cell migration,
invasion and EMT via the down regulation of snail, slug, twist, and
MMP1/9. J Physiol Biochem. 76:73–83. 2020. View Article : Google Scholar
|
|
135
|
Wang J, Yang S, He P, Schetter AJ, Gaedcke
J, Ghadimi BM, Ried T, Yfantis HG, Lee DH, Gaida MM, et al:
Endothelial nitric oxide synthase traffic inducer (NOSTRIN) is a
negative regulator of disease aggressiveness in pancreatic cancer.
Clin Cancer Res. 22:5992–6001. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Herner A, Sauliunaite D, Michalski CW,
Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H
and Kleeff J: Glutamate increases pancreatic cancer cell invasion
and migration via AMPA receptor activation and Kras-MAPK signaling.
Int J Cancer. 129:2349–2359. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Gitto SB, Pandey V, Oyer JL, Copik AJ,
Hogan FC, Phanstiel O IV and Altomare DA: Difluoromethylornithine
combined with a polyamine transport inhibitor is effective against
gemcitabine resistant pancreatic cancer. Mol Pharm. 15:369–376.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Kremer JC, Prudner BC, Lange SES, Bean GR,
Schultze MB, Brashears CB, Radyk MD, Redlich N, Tzeng SC, Kami K,
et al: Arginine deprivation inhibits the Warburg effect and
upregulates glutamine anaplerosis and serine biosynthesis in
ASS1-deficient cancers. Cell Rep. 18:991–1004. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Davidson SM, Jonas O, Keibler MA, Hou HW,
Luengo A, Mayers JR, Wyckoff J, Del Rosario AM, Whitman M, Chin CR,
et al: Direct evidence for cancer-cell-autonomous extracellular
protein catabolism in pancreatic tumors. Nat Med. 23:235–241. 2017.
View Article : Google Scholar
|
|
140
|
Maertin S, Elperin JM, Lotshaw E, Sendler
M, Speakman SD, Takakura K, Reicher BM, Mareninova OA, Grippo PJ,
Mayerle J, et al: Roles of autophagy and metabolism in pancreatic
cancer cell adaptation to environmental challenges. Am J Physiol
Gastrointest Liver Physiol. 313:G524–G536. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Saliakoura M, Sebastiano MR, Nikdima I,
Pozzato C and Konstantinidou G: Restriction of extracellular lipids
renders pancreatic cancer dependent on autophagy. J Exp Clin Cancer
Res. 41:162022. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Piffoux M, Eriau E and Cassier PA:
Autophagy as a therapeutic target in pancreatic cancer. Br J
Cancer. 124:333–344. 2021. View Article : Google Scholar :
|
|
143
|
Li J, Chen X, Kang R, Zeh H, Klionsky DJ
and Tang D: Regulation and function of autophagy in pancreatic
cancer. Autophagy. 17:3275–3296. 2021. View Article : Google Scholar :
|
|
144
|
Yamamoto K, Venida A, Yano J, Biancur DE,
Kakiuchi M, Gupta S, Sohn ASW, Mukhopadhyay S, Lin EY, Parker SJ,
et al: Autophagy promotes immune evasion of pancreatic cancer by
degrading MHC-I. Nature. 581:100–105. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Mukhopadhyay S, Biancur DE, Parker SJ,
Yamamoto K, Banh RS, Paulo JA, Mancias JD and Kimmelman AC:
Autophagy is required for proper cysteine homeostasis in pancreatic
cancer through regulation of SLC7A11. Proc Natl Acad Sci USA.
118:e20214751182021. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Ashton TM, Gillies McKenna W,
Kunz-Schughart LA and Higgins GS: Oxidative phosphorylation as an
emerging target in cancer therapy. Clin Cancer Res. 24:2482–2490.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Zong WX, Rabinowitz JD and White E:
Mitochondria and cancer. Mol Cell. 61:667–676. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Lambert A and Brand M: Reactive oxygen
species production by mitochondria. Methods Mol Biol. 554:165–181.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Weinberg F, Hamanaka R, Wheaton WW,
Weinberg S, Joseph J, Lopez M, Kalyanaraman B, Mutlu GM, Budinger
GR and Chandel NS: Mitochondrial metabolism and ROS generation are
essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA.
107:8788–8793. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Nevala-Plagemann C, Hidalgo M and
Garrido-Laguna I: From state-of-the-art treatments to novel
therapies for advanced-stage pancreatic cancer. Nat Rev Clin Oncol.
17:108–123. 2020. View Article : Google Scholar
|
|
151
|
Masoud R, Reyes-Castellanos G, Lac S,
Garcia J, Dou S, Shintu L, Abdel Hadi N, Gicquel T, El Kaoutari A,
Diémé B, et al: Targeting mitochondrial complex I overcomes
chemoresistance in high OXPHOS pancreatic cancer. Cell Rep Med.
1:1001432020. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Candido S, Abrams SL, Steelman L,
Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata
RM, Rosalen PL, et al: Metformin influences drug sensitivity in
pancreatic cancer cells. Adv Biol Regul. 68:13–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Zannella VE, Dal Pra A, Muaddi H, McKee
TD, Stapleton S, Sykes J, Glicksman R, Chaib S, Zamiara P,
Milosevic M, et al: Reprogramming metabolism with metformin
improves tumor oxygenation and radiotherapy response. Clin Cancer
Res. 19:6741–6750. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Neesse A, Bauer CA, Öhlund D, Lauth M,
Buchholz M, Michl P, Tuveson DA and Gress TM: Stromal biology and
therapy in pancreatic cancer: Ready for clinical translation? Gut.
68:159–171. 2019. View Article : Google Scholar
|
|
155
|
Croucher DR, Saunders DN, Lobov S and
Ranson M: Revisiting the biological roles of PAI2 (SERPINB2) in
cancer. Nat Rev Cancer. 8:535–545. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Harris NLE, Vennin C, Conway JRW, Vine KL,
Pinese M, Cowley MJ, Shearer RF, Lucas MC, Herrmann D, Allam AH, et
al: SerpinB2 regulates stromal remodelling and local invasion in
pancreatic cancer. Oncogene. 36:4288–4298. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Jiang B, Zhou L, Lu J, Wang Y, Liu C, You
L and Guo J: Stroma-targeting therapy in pancreatic cancer: One
coin with two sides? Front Oncol. 10:5763992020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Rhim AD, Oberstein PE, Thomas DH, Mirek
ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP,
Tattersall IW, et al: Stromal elements act to restrain, rather than
support, pancreatic ductal adenocarcinoma. Cancer Cell. 25:735–747.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
de la Fouchardière C, Gamradt P, Chabaud
S, Raddaz M, Blanc E, Msika O, Treilleux I, Bachy S,
Cattey-Javouhey A, Guibert P, et al: A promising biomarker and
therapeutic target in patients with advanced PDAC: The stromal
protein βig-h3. J Pers Med. 12:6232022. View Article : Google Scholar
|
|
160
|
Olive KP, Jacobetz MA, Davidson CJ,
Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA,
Caldwell ME, Allard D, et al: Inhibition of hedgehog signaling
enhances delivery of chemotherapy in a mouse model of pancreatic
cancer. Science. 324:1457–1461. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Bulle A and Lim KH: Beyond just a tight
fortress: Contribution of stroma to epithelial-mesenchymal
transition in pancreatic cancer. Signal Transduct Target Ther.
5:2492020. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Malchiodi ZX, Cao H, Gay MD, Safronenka A,
Bansal S, Tucker RD, Weinberg BA, Cheema A, Shivapurkar N and Smith
JP: Cholecystokinin receptor antagonist improves efficacy of
chemotherapy in murine models of pancreatic cancer by altering the
tumor microenvironment. Cancers (Basel). 13:49492021. View Article : Google Scholar
|
|
163
|
Lee JJ, Perera RM, Wang H, Wu DC, Liu XS,
Han S, Fitamant J, Jones PD, Ghanta KS, Kawano S, et al: Stromal
response to hedgehog signaling restrains pancreatic cancer
progression. Proc Natl Acad Sci USA. 111:E3091–E3100. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Wu Y, Zhang C, Jiang K, Werner J, Bazhin
AV and D'Haese JG: The role of stellate cells in pancreatic ductal
adenocarcinoma: Targeting perspectives. Front Oncol. 10:6219372021.
View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Lisanti MP, Martinez-Outschoorn UE,
Chiavarina B, Pavlides S, Whitaker-Menezes D, Tsirigos A,
Witkiewicz A, Lin Z, Balliet R, Howell A and Sotgia F:
Understanding the 'lethal' drivers of tumor-stroma co-evolution:
Emerging role(s) for hypoxia, oxidative stress and
autophagy/mitophagy in the tumor micro-environment. Cancer Biol
Ther. 10:537–542. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Ko YH, Lin Z, Flomenberg N, Pestell RG,
Howell A, Sotgia F, Lisanti MP and Martinez-Outschoorn UE:
Glutamine fuels a vicious cycle of autophagy in the tumor stroma
and oxidative mitochondrial metabolism in epithelial cancer cells:
Implications for preventing chemotherapy resistance. Cancer Biol
Ther. 12:1085–1097. 2011. View Article : Google Scholar
|
|
167
|
Mariño G and Kroemer G: Ammonia: A
diffusible factor released by proliferating cells that induces
autophagy. Sci Signal. 3:pe192010. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Zhao H, Yang L, Baddour J, Achreja A,
Bernard V, Moss T, Marini JC, Tudawe T, Seviour EG, San Lucas FA,
et al: Tumor microenvironment derived exosomes pleiotropically
modulate cancer cell metabolism. Elife. 5:e102502016. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Waldenmaier M, Seibold T, Seufferlein T
and Eiseler T: Pancreatic cancer small extracellular vesicles
(exosomes): A tale of short- and long-distance communication.
Cancers (Basel). 13:48442021. View Article : Google Scholar
|
|
170
|
Takikawa T, Masamune A, Yoshida N, Hamada
S, Kogure T and Shimosegawa T: Exosomes derived from pancreatic
stellate cells: MicroRNA signature and effects on pancreatic cancer
cells. Pancreas. 46:19–27. 2017. View Article : Google Scholar
|
|
171
|
Mullen AR, Wheaton WW, Jin ES, Chen PH,
Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS and
DeBerardinis RJ: Reductive carboxylation supports growth in tumour
cells with defective mitochondria. Nature. 481:385–388. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Olivares O, Mayers JR, Gouirand V,
Torrence ME, Gicquel T, Borge L, Lac S, Roques J, Lavaut MN,
Berthezène P, et al: Collagen-derived proline promotes pancreatic
ductal adenocarcinoma cell survival under nutrient limited
conditions. Nat Commun. 8:160312017. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Begum A, McMillan RH, Chang YT, Penchev
VR, Rajeshkumar NV, Maitra A, Goggins MG, Eshelman JR, Wolfgang CL,
Rasheed ZA and Matsui W: Direct interactions with cancer-associated
fibroblasts lead to enhanced pancreatic cancer stem cell function.
Pancreas. 48:329–334. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Cai Z, Liang Y, Xing C, Wang H, Hu P, Li
J, Huang H, Wang W and Jiang C: Cancer-associated adipocytes
exhibit distinct phenotypes and facilitate tumor progression in
pancreatic cancer. Oncol Rep. 42:2537–2549. 2019.PubMed/NCBI
|
|
175
|
Meyer KA, Neeley CK, Baker NA, Washabaugh
AR, Flesher CG, Nelson BS, Frankel TL, Lumeng CN, Lyssiotis CA,
Wynn ML, et al: Adipocytes promote pancreatic cancer cell
proliferation via glutamine transfer. Biochem Biophys Rep.
7:144–149. 2016.PubMed/NCBI
|
|
176
|
Ye H, Zhou Q, Zheng S, Li G, Lin Q, Wei L,
Fu Z, Zhang B, Liu Y, Li Z and Chen R: Tumor-associated macrophages
promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1
pathway in pancreatic ductal adenocarcinoma. Cell Death Dis.
9:4532018. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Asencio-Barría C, Defamie N, Sáez JC,
Mesnil M and Godoy AS: Direct intercellular communications and
cancer: A snapshot of the biological roles of connexins in prostate
cancer. Cancers (Basel). 11:13702019. View Article : Google Scholar
|
|
178
|
Luo M, Luo Y, Mao N, Huang G, Teng C, Wang
H, Wu J, Liao X and Yang J: Cancer-associated fibroblasts
accelerate malignant progression of non-small cell lung cancer via
connexin 43-formed unidirectional gap junctional intercellular
communication. Cell Physiol Biochem. 51:315–336. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Wang J, Liu X, Qiu Y, Shi Y, Cai J, Wang
B, Wei X, Ke Q, Sui X, Wang Y, et al: Cell adhesion-mediated
mitochondria transfer contributes to mesenchymal stem cell-induced
chemoresistance on T cell acute lymphoblastic leukemia cells. J
Hematol Oncol. 11:112018. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Marlein CR, Piddock RE, Mistry JJ,
Zaitseva L, Hellmich C, Horton RH, Zhou Z, Auger MJ, Bowles KM and
Rushworth SA: CD38-driven mitochondrial trafficking promotes
bioenergetic plasticity in multiple myeloma. Cancer Res.
79:2285–2297. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Dovmark TH, Saccomano M, Hulikova A, Alves
F and Swietach P: Connexin-43 channels are a pathway for
discharging lactate from glycolytic pancreatic ductal
adenocarcinoma cells. Oncogene. 36:4538–4550. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Yu Z, Pestell TG, Lisanti MP and Pestell
RG: Cancer stem cells. Int J Biochem Cell Biol. 44:2144–2151. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Mummery CL, van de Stolpe A, Roelen B and
Clevers H: Chapter 12-Cancer stem cells: Where do they come from
and where are they going? Stem Cells. 3rd. Mummery CL, van de
Stolpe A, Roelen B and Clevers HB: Academic Press; Boston: pp.
299–328. 2021, View Article : Google Scholar
|
|
184
|
Nguyen LV, Vanner R, Dirks P and Eaves CJ:
Cancer stem cells: An evolving concept. Nat Rev Cancer. 12:133–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Li C, Heidt DG, Dalerba P, Burant CF,
Zhang L, Adsay V, Wicha M, Clarke MF and Simeone DM: Identification
of pancreatic cancer stem cells. Cancer Res. 67:1030–1038. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Gzil A, Zarębska I, Bursiewicz W, Antosik
P, Grzanka D and Szylberg Ł: Markers of pancreatic cancer stem
cells and their clinical and therapeutic implications. Mol Biol
Rep. 46:6629–6645. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Hermann PC, Huber SL, Herrler T, Aicher A,
Ellwart JW, Guba M, Bruns CJ and Heeschen C: Distinct populations
of cancer stem cells determine tumor growth and metastatic activity
in human pancreatic cancer. Cell Stem Cell. 1:313–323. 2007.
View Article : Google Scholar
|
|
188
|
Rasheed ZA, Yang J, Wang Q, Kowalski J,
Freed I, Murter C, Hong SM, Koorstra JB, Rajeshkumar NV, He X, et
al: Prognostic significance of tumorigenic cells with mesenchymal
features in pancreatic adenocarcinoma. J Natl Cancer Inst.
102:340–351. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Li C, Wu JJ, Hynes M, Dosch J, Sarkar B,
Welling TH, Pasca di Magliano M and Simeone DM: c-Met is a marker
of pancreatic cancer stem cells and therapeutic target.
Gastroenterology. 141:2218–2227.e5. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Miranda-Lorenzo I, Dorado J, Lonardo E,
Alcala S, Serrano AG, Clausell-Tormos J, Cioffi M, Megias D,
Zagorac S, Balic A, et al: Intracellular autofluorescence: A
biomarker for epithelial cancer stem cells. Nat Methods.
11:1161–1169. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Sancho P, Alcala S, Usachov V, Hermann PC
and Sainz B Jr: The ever-changing landscape of pancreatic cancer
stem cells. Pancreatology. 16:489–496. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Depeint F, Bruce WR, Shangari N, Mehta R
and O'Brien PJ: Mitochondrial function and toxicity: Role of the B
vitamin family on mitochondrial energy metabolism. Chem Biol
Interact. 163:94–112. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Rovira M, Scott SG, Liss AS, Jensen J,
Thayer SP and Leach SD: Isolation and characterization of
centroacinar/terminal ductal progenitor cells in adult mouse
pancreas. Proc Natl Acad Sci USA. 107:75–80. 2010. View Article : Google Scholar :
|
|
194
|
Sainz BJ Jr, Alcala S, Garcia E,
Sanchez-Ripoll Y, Azevedo MM, Cioffi M, Tatari M, Miranda-Lorenzo
I, Hidalgo M, Gomez-Lopez G, et al: Microenvironmental
hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by
activating its cancer stem cell compartment. Gut. 64:1921–1935.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Sainz B Jr, Martín B, Tatari M, Heeschen C
and Guerra S: ISG15 is a critical microenvironmental factor for
pancreatic cancer stem cells. Cancer Res. 74:7309–7320. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Rausch V, Liu L, Apel A, Rettig T,
Gladkich J, Labsch S, Kallifatidis G, Kaczorowski A, Groth A, Gross
W, et al: Autophagy mediates survival of pancreatic
tumour-initiating cells in a hypoxic microenvironment. J Pathol.
227:325–335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Zhu H, Wang D, Zhang L, Xie X, Wu Y, Liu
Y, Shao G and Su Z: Upregulation of autophagy by hypoxia-inducible
factor-1α promotes EMT and metastatic ability of CD133+ pancreatic
cancer stem-like cells during intermittent hypoxia. Oncol Rep.
32:935–942. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Jagust P, Alcalá S, Sainz B Jr, Heeschen C
and Sancho P: Glutathione metabolism is essential for self-renewal
and chemoresistance of pancreatic cancer stem cells. World J Stem
Cells. 12:1410–1428. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Li D, Fu Z, Chen R, Zhao X, Zhou Y, Zeng
B, Yu M, Zhou Q, Lin Q, Gao W, et al: Inhibition of glutamine
metabolism counteracts pancreatic cancer stem cell features and
sensitizes cells to radiotherapy. Oncotarget. 6:31151–31163. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Brandi J, Dando I, Pozza ED, Biondani G,
Jenkins R, Elliott V, Park K, Fanelli G, Zolla L, Costello E, et
al: Proteomic analysis of pancreatic cancer stem cells: Functional
role of fatty acid synthesis and mevalonate pathways. J Proteomics.
150:310–322. 2017. View Article : Google Scholar
|
|
201
|
McDonald OG, Li X, Saunders T,
Tryggvadottir R, Mentch SJ, Warmoes MO, Word AE, Carrer A, Salz TH,
Natsume S, et al: Epigenomic reprogramming during pancreatic cancer
progression links anabolic glucose metabolism to distant
metastasis. Nat Genet. 49:367–376. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Alcalá S, Sancho P, Martinelli P, Navarro
D, Pedrero C, Martín-Hijano L, Valle S, Earl J, Rodríguez-Serrano
M, Ruiz-Cañas L, et al: ISG15 and ISGylation is required for
pancreatic cancer stem cell mitophagy and metabolic plasticity. Nat
Commun. 11:26822020. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Nimmakayala RK, Leon F, Rachagani S, Rauth
S, Nallasamy P, Marimuthu S, Shailendra GK, Chhonker YS, Chugh S,
Chirravuri R, et al: Metabolic programming of distinct cancer stem
cells promotes metastasis of pancreatic ductal adenocarcinoma.
Oncogene. 40:215–231. 2021. View Article : Google Scholar
|
|
204
|
Alistar A, Morris BB, Desnoyer R, Klepin
HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R
Jr, Topaloglu U, et al: Safety and tolerability of the
first-in-class agent CPI-613 in combination with modified
FOLFIRINOX in patients with metastatic pancreatic cancer: A
single-centre, open-label, dose-escalation, phase 1 trial. Lancet
Oncol. 18:770–778. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Philip PA, Buyse ME, Alistar AT, Rocha
Lima CM, Luther S, Pardee TS and Van Cutsem E: A phase III
open-label trial to evaluate efficacy and safety of CPI-613 plus
modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with
metastatic adenocarcinoma of the pancreas. Future Oncol.
15:3189–3196. 2019. View Article : Google Scholar : PubMed/NCBI
|
